Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Sofinnova Management VIII, L.L.C. (CIK 1559565) reported $183.2M across 7 reported positions in its SEC 13F filing for 2017-12-31. Largest positions: NCNA ($47.2M, 25.76%), OBSVF ($46.4M, 25.31%), ACRS ($38.0M, 20.72%), ONCE ($24.7M, 13.51%), NTRA ($13.9M, 7.61%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | NCNA | NuCana plc | $47.2M | 25.76% | 4.7M | Added |
| 2 | OBSVF | ObsEva SA | $46.4M | 25.31% | 4.7M | Added |
| 3 | ACRS | Aclaris Therapeutics, Inc. | $38.0M | 20.72% | 1.5M | Hold |
| 4 | ONCE | Spark Therapeutics, Inc. | $24.7M | 13.51% | 481,270 | Hold |
| 5 | NTRA | Natera, Inc. | $13.9M | 7.61% | 1.6M | Hold |
| 6 | Auris Medical Holding AG | $4.6M | 2.52% | 7.8M | Hold | |
| 7 | OCGN | Histogenics Corporation | $4.3M | 2.32% | 2.1M | Hold |
| 8 | SYBX | Synlogic, Inc. | $4.1M | 2.25% | 424,972 | Hold |
Source: SEC Form 13F filings · as of 2017-12-31